Levocarnitine for pegaspargase‐induced hepatotoxicity in older children and young adults with acute lymphoblastic leukemia

BACKGROUND: Pegaspargase (PEG‐ASP) is an integral component of therapy for acute lymphoblastic leukemia (ALL) but is associated with hepatotoxicity that may delay or limit future therapy. Obese and adolescent and young adult (AYA) patients are at high risk. Levocarnitine has been described as potent...

Descripción completa

Detalles Bibliográficos
Autores principales: Schulte, Rachael, Hinson, Ashley, Huynh, Van, Breese, Erin H., Pierro, Joanna, Rotz, Seth, Mixon, Benjamin A., McNeer, Jennifer L., Burke, Michael J., Orgel, Etan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559504/
https://www.ncbi.nlm.nih.gov/pubmed/34528411
http://dx.doi.org/10.1002/cam4.4281

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559504/
https://www.ncbi.nlm.nih.gov/pubmed/34528411
http://dx.doi.org/10.1002/cam4.4281

Ejemplares similares